Relativity Healthcare Partners
8
23M
8
1
- Areas of investment
Summary
Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has exact preference in some founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Health Care, Manufacturing. Among the most popular portfolio startups of the fund, we may highlight Earlens Corporation, BioAnalytix, BeneStream.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2019. The fund is generally included in less than 2 deals every year. The top activity for fund was in 2017.
The usual cause for the fund is to invest in rounds with 6 partakers. Despite the Relativity Healthcare Partners, startups are often financed by Vertex Ventures HC, Vertex Ventures, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, WuXi Healthcare Ventures, Windham Venture Partners. In the next rounds fund is usually obtained by HOYA Group, Sandbox Industries, BlueCross BlueShield Venture Partners.
Investments analytics
Analytics
- Total investments
- 8
- Lead investments
- 0
- Exits
- 1
- Investments by industry
- Medical (5)
- Biotechnology (4)
- Health Care (4)
- Pharmaceutical (3)
- Medical Device (2) Show 7 more
- Investments by region
-
- United States (8)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 15
- Avg. valuation at time of investment
- 1M
- Group Appearance index
- 0.88
- Avg. company exit year
- 8
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| OrphoMed | 24 May 2017 | Biotechnology, Medical, Pharmaceutical | Early Stage Venture | 39M | United States, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.